Advanced search
Publication Cover
Leukemia & Lymphoma Volume 61, 2020 - Issue 13
Submit an article Journal homepage
280
Views
3
CrossRef citations to date
0
Altmetric
Letters to the Editor

Clonal evolution with acquisition of BCR-ABL1 in refractory acute myeloid leukemia post therapy with FLT3-inhibitor

Beenu Thakrala Department of Hematopathology, MD Anderson Cancer Center, Houston, TX, USACorrespondence[email protected]
,
Naval Daverb Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA
,
Zhenya Tanga Department of Hematopathology, MD Anderson Cancer Center, Houston, TX, USA
,
Keyur P. Patela Department of Hematopathology, MD Anderson Cancer Center, Houston, TX, USA
,
Chi Young Oka Department of Hematopathology, MD Anderson Cancer Center, Houston, TX, USA
,
Sanam Loghavia Department of Hematopathology, MD Anderson Cancer Center, Houston, TX, USA
,
Joseph D. Khourya Department of Hematopathology, MD Anderson Cancer Center, Houston, TX, USA
,
Ahmad S. Alotaibib Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA
,
Marina Konoplevab Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA
,
Musa Yilmazb Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA
&
L. Jeffrey Medeirosa Department of Hematopathology, MD Anderson Cancer Center, Houston, TX, USA
 show all
Pages 3243-3246 | Received 11 May 2020, Accepted 13 Jul 2020, Published online: 22 Jul 2020

References

  • Daver N, Schlenk RF, Russell NH, et al. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019;33(2):299–312.
  • Frohling S, Schlenk RF, Breitruck J, et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood. 2002;100(13):4372–4380.
  • Levis M, Perl AE. Gilteritinib: potent targeting of FLT3 mutations in AML. Blood Adv. 2020;4(6):1178–1191.
  • Soderquist CR, Ewalt MD, Czuchlewski DR, et al. Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group. Mod Pathol. 2018; 31(5):690–704.
  • Aoki J, Kakihana K, Kobayashi T, et al. Tyrosine kinase inhibitor therapy for acute myeloid leukemia with late-appearing Philadelphia chromosome. Leuk Res. 2012;36(1):e41–e42.
  • Esteve J, Schots R, Del Castillo TB, et al. Multicenter, open-label, 3-arm study of gilteritnib, gilteritinib plus azacitidinem or azacitidine alone in newly diagnosed FLT3 mutated (FLT3 mut+) acute myeloid leukemia (AML) patients ineligible for intensive induction chemotherapy: findings from the safety cohort. Blood. 2018;132(Supplement 1):2736–2736.
  • Perl AE, Daver N, Pratz KW, et al. Venetoclax in combination with gilteritinib in patients with relapsed/refractory acute myeloid leukemia: a phase 1b study. Blood. 2019;134(Supplement_1):3910–3910.
  • Shah NP, Talpaz M, Deininger MWN, et al. Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 study. Br J Haematol. 2013; 162(4):548–552.
  • Smith CC, Lasater EA, Zhu X, et al. Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD. Blood. 2013;121(16):3165–3171.
  • Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405.
  • Shimamoto T, Ohyashiki K, Ohyashiki JH, et al. Late appearance of a Philadelphia translocation with minor BCR-ABL transcript in a t(7;11) (p15;p15) acute myeloid leukemia. Leukemia. 1995;9:640–642.
  • Shah NP, Leaker MT, Teshima I, et al. Late-appearing Philadelphia chromosome in childhood acute myeloid leukemia. Pediatr Blood Cancer. 2008;50(5):1052–1053.
  • Keung YK, Beaty M, Powell BL, et al. Philadelphia chromosome positive myelodysplastic syndrome and acute myeloid leukemia-retrospective study and review of literature. Leuk Res. 2004;28(6):579–586.
  • Bacher U, Haferlach T, Alpermann T, et al. Subclones with the t(9;22)/BCR-ABL1 rearrangement occur in AML and seem to cooperate with distinct genetic alterations. Br J Haematol. 2011;152(6):713–720.
  • Verhoef G, Meeus P, Stul M, et al. Cytogenetic and molecular studies of the Philadelphilia translocation in myelodysplastic syndromes. Report of two cases and review of the literature. Cancer Genet Cytogenet. 1992;59(2):161–166.
  • Neuendorff NR, Schwarz M, Hemmati P, et al. BCR-ABL1(+) acute myeloid leukemia: clonal selection of a BCR-ABL1(–) subclone as a cause of refractory disease with nilotinib treatment. Acta Haematol. 2015;133(2):237–241.
  • Kurt H, Zheng L, Kantarjian HM, et al. Secondary Philadelphia chromosome acquired during therapy of acute leukemia and myelodysplastic syndrome. Mod Pathol. 2018;31(7):1141–1154.
  • Chen L, Stamatoullas A, Bastard C, et al. Secondary Philadelphia chromosome in a patient with acute lymphoblastic leukemia. Cancer Genet Cytogenet. 2004;152(2):132–135.
  • Boddu P, Gibbons J, Burger J, et al. Co-occurrence of chronic myeloid leukemia with chronic lymphocytic leukemia: a report of two cases. Leuk Lymphoma. 2019;60(6):1568–1571.
  • Chen Z, Wang W, Verstovsek S, et al. Chronic myelogenous leukemia in patients with MPL or JAK2 mutation-positive myeloproliferative neoplasm . Int J Lab Hematol. 2015;37(6):e150–e152.
  • Kasi PM, Litzow MR, Patnaik MM, et al. Clonal evolution of AML on novel FMS-like tyrosine kinase-3 (FLT3) inhibitor therapy with evolving actionable targets. Leuk Res Rep. 2016;5:7–16.
  • McMahon CM, Ferng T, Canaani J, et al. Clonal selection with RAS pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia. Cancer Discov. 2019;9(8):1050–1063.
  • Piloto O, Wright M, Brown P, et al. Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways. Blood. 2007;109(4):1643–1652.
  • Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med. 2019;381(18):1728–1740.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.